Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
All content for The Swiss Connection is the property of SWI swissinfo.ch and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
Herwig Schopper, Former CERN head has served science and peace for 100 years
The Swiss Connection
18 minutes
1 year ago
Herwig Schopper, Former CERN head has served science and peace for 100 years
Send us a text Swissinfo talks to Herwig Schopper, former CERN director, the grandfather of the world’s most powerful particle accelerator, who helped promote peace through a Middle Eastern science hub and has his qualms about the Nobel Prize. If Herwig Schopper has learned anything during his 100 years on Earth, it’s that breakthroughs only happen when we work together. Please read here this interview and the full biography of Herwig Schopper, and please come to Swissinfo.ch fo...
The Swiss Connection
Send us a text We trace how sex and gender shape drug development, from male-heavy mouse studies to the split results in Lecanemab’s Alzheimer’s trial. Experts explain why regulators should keep approvals moving while demanding smarter design, better reporting, and post-approval answers. For more science stories, visit our website swisinfo.ch, and you can help other people to find our podcast by leaving us a five-star review. Journalist: Jessica Davis Plüss Host: Jo Fahy Audio editor/vide...
